RT Journal Article
T1 A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium
A1 Lindström, Sara
A1 Ma, Jing
A1 Altshuler, David
A1 Giovannucci, Edward
A1 Riboli, Elio
A1 Albanes, Demetrius
A1 Allen, Naomi E
A1 Berndt, Sonja I
A1 Boeing, Heiner
A1 Bueno de Mesquita, H Bas
A1 Chanock, Stephen J
A1 Dunning, Alison M
A1 Spencer Feigelson, Heather
A1 Gaziano, J Michael
A1 Haiman, Christopher A
A1 Hayes, Richard B
A1 Henderson, Brian E
A1 Hunter, David J
A1 Kaaks, Rudolf
A1 Kolonel, Laurence N
A1 Le Marchand, Loic
A1 Martínez, Carmen
A1 Overvad, Kim
A1 Siddiq, Afshan
A1 Stampfer, Meir
A1 Stattin, Pär
A1 Stram, Daniel O
A1 Thun, Michael J
A1 Trichopoulos, Dimitrios
A1 Tumino, Rosario
A1 Virtamo, Jarmo
A1 Weinstein, Stephanie J
A1 Yeager, Meredith
A1 Kraft, Peter
A1 Freedman, Matthew L
K1 Neoplasias de la próstata
K1 Hormonas esteroides gonadales
K1 Receptores androgénicos
K1 Estudios de asociación genética
K1 Estudios de cohortes
AB Background: Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. A long-standing hypothesis has been that inherited variation in the androgen receptor (AR) gene plays a role in prostate cancer initiation. However, studies to date have been inconclusive and often suffered from small sample sizes. Objective and Methods: We investigated the association of AR sequence variants with circulating sex hormone levels and prostate cancer risk in 6058 prostate cancer cases and 6725 controls of Caucasian origin within the Breast and Prostate Cancer Cohort Consortium. We genotyped a highly polymorphic CAG microsatellite in exon 1 and six haplotype tagging single nucleotide polymorphisms and tested each genetic variant for association with prostate cancer risk and with sex steroid levels. Results: We observed no association between AR genetic variants and prostate cancer risk. However, there was a strong association between longer CAG repeats and higher levels of testosterone (P = 4.73 × 10−5) and estradiol (P = 0.0002), although the amount of variance explained was small (0.4 and 0.7%, respectively). Conclusions: This study is the largest to date investigating AR sequence variants, sex steroid levels, and prostate cancer risk. Although we observed no association between AR sequence variants and prostate cancer risk, our results support earlier findings of a relation between the number of CAG repeats and circulating levels of testosterone and estradiol.
PB Endocrine Society
YR 2010
FD 2010-09-01
LK http://hdl.handle.net/10668/392
UL http://hdl.handle.net/10668/392
LA es
NO Lindström S, Ma J, Altshuler D, Giovannucci E, Riboli E, Albanes D, et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010 Sep;95(9):E121-7
DS RISalud
RD Apr 7, 2025